Description
ARTRIO-TZ 1.125 Injection contains 100 mg of Cefriaxone and 125 mg of Tazobactam per vial. It is a combination antibiotic injection that is used for the management of certain bacterial infections under the guidance of a qualified healthcare professional. Ceftriaxone works by stopping bacteria from forming their protective cell wall, which helps to control bacterial growth, while Tazobactam helps to block certain enzymes, called beta-lactamases, that can reduce the effectiveness of some antibiotics. This combination can therefore help to improve the activity of Ceftriaxone against susceptible bacteria.Â
ARTRIO-TZ 1.125 injection is available in 1-pack and is listed by Senen Biotech under its Arohan and injectable product ranges. It can be considered for hospital and clinical pharmaceutical portfolios where appropriate.
Uses of ARTRIO-TZ 1.125 Injection
ARTRIO-TZ 1.125 may be prescribed for the management of susceptible bacterial infections, including:
- Respiratory tract infections
- Pneumonia
- Urinary tract infections
- Skin and soft-tissue infections
- Bone and joint infections
- Intra-abdominal infections
- Gynecological infections
- Bloodstream infections such as septicemia
- Certain post-surgical bacterial infections
- Other complicated bacterial infections caused by susceptible organisms
PCD Pharma Franchise Opportunity for Cefriaxone and Tazobactam Injection – Senen Biotech
Cefriaxone and Tazobactam Injection can be a useful addition to a PCD pharma franchise product portfolio, especially for entrepreneurs and distributors who are focusing on antibiotics, injectables, hospital care, and critical-care products.Â
Senen Biotech offers ARTRIO-TZ 1.125 as part of its pharmaceutical range, along with other injectable and anti-infective products, such as Ceftriaxone, Cefoperazone-Sulbactam, Amikacin, and more.Â
For PCD Franchise partners, Ceftriaxone and Tazobactam Injection can help to expand their antibiotic product range and offer an additional injectable combination for suitable healthcare markets. Franchise partners can promote it along with other relevant products in their assigned territory.
Why Add ARTRIO-TZ 1.125 to Your PCD Portfolio?
- Ceftriaxone 1000 mg + Tazobactam 125 mg combination
- Convenient 1.125 g injectable presentation
- Suitable for hospital and clinical segments
- Can complement other antibiotic products
- Relevant addition to an injectable pharmaceutical portfolio
- Suitable for pharmaceutical distributors and PCD franchise partners
- Listed within Senen Biotech’s PCD product range




